News

Company Announcements

›

News

and

Publications

Stay in the loop

Thank you for subscribing!

Oops! Something went wrong while submitting the form.

Beckley Psytech applies for B Corporation status as part of its commitment to have a positive impact on society

B Corporations represent a new kind of business philosophy to protect and develop the future of all stakeholders.

Beckley Psytech to attend 11th Annual LifeSci Partners Virtual Corporate Access Event

CEO to participate in a panel discussion on the topic of “Psychedelics: More Than Just a Trip” – January 5, 2022 at 10:00 am ET / 3:00 pm GMT

Beckley Psytech to present at H.C. Wainwright 2nd Annual Psychedelics Conference and Stifel 2nd Annual Conference “The Future of Healthcare”

Cosmo Feilding Mellen will present at the H.C. Wainwright 2nd Annual Psychedelics Conference, taking place virtually on December 6th, 2021, and the Stifel 2nd annual conference The Future of Healthcare, taking place virtually on December 8th, 2021.

Enhancing the accessibility of psychedelic healthcare

‘The combination of the drug and psychotherapy is critical. What will be interesting to see is how the healthcare infrastructure reacts to that...'

Brunch with Sifted: Amanda Feilding and Cosmo Feilding-Mellen on the psychedelic renaissance

“The logic behind setting up Beckley Psytech was that there’s this body of evidence that’s been generated in an academic setting, in early stage, proof of concept settings.

Dr Frank Wiegand, experienced neuroscience leader joins Beckley Psytech as Chief Medical Officer

Oxford, United Kingdom – 3 November 2021 - Beckley Psytech, a privately owned, clinical stage, biotechnology company dedicated to addressing neuropsychiatric disorders through the novel application of psychedelic medicines, has today announced the appointment of Frank Wiegand MD. PhD. as Chief Medical Officer.

Beckley Psytech to present at Jefferies 2021 London Healthcare Conference

Cosmo Feilding Mellen, Chief Executive Officer, to present at the Jefferies 2021 London Healthcare Conference, taking place in-person and virtually from 16th to 19th November, 2021.

Beckley Psytech announces first cohort dosed in Phase 1 clinical trial assessing safety and tolerability of intranasal 5-MeO-DMT

Phase 1 trial is evaluating the safety and tolerability of a novel formulation of intranasal 5-MeO-DMT Study will measure detailed pharmacokinetics and metabolism of 5-MeO-DMT in healthy volunteers Preliminary data, expected H1 2022, to support Phase 2 study designs investigating the use of 5-MeO-DMT in treatment resistant depression (TRD) and other neuropsychiatric indications

The Psychedelics as Medicine Report: Third Edition

The Psychedelics as Medicine Report: Third Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping investors cut through the noise and identify real opportunities.

Beckley Psytech announces first patient has received low-dose psilocybin in world-first clinical trial for rare headache disorder

World-first phase 1 trial will evaluate efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA) Data expected in early 2022 SUNHA, a rare and debilitating headache condition, is estimated to affect 40,000 patients in US and Europe

Featured on